Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
Rigopoulos
Dimitrios
D
Gregoriou
Stamatis
S
Katsambas
Andreas
A
D000287:Administration, Topical; D002990:Clobetasol / Q000008:administration & dosage* / Q000009:adverse effects; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D009260:Nail Diseases / Q000188:drug therapy*; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids
D002990:Clobetasol; D003879:Dermatologic Agents; D007641:Keratolytic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids